Abstracts tagged "Disease Activity"

Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2570 • 2018 ACR/ARHP Annual Meeting
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Philip J. Mease¹, Frank Behrens², Dafna D Gladman³, Arthur Kavanaugh⁴, Michele Brunori⁵, Lichen Teng⁵, Benoit Guerette⁵, Rubén Queiro⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California, San Diego, School of Medicine, La Jolla, CA, ⁵Celgene Corporation, Summit, NJ, ⁶Rheum-Derm Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The ability to predict responses to apremilast (APR) could impact treatment decisions. This post-hoc analysis was conducted to (1) assess the predictive values of…
Abstract Number: 2889 • 2018 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
Philip J. Mease¹, Shelly Kafka², Soumya D Chakravarty³, Diane D. Harrison⁴, Kim Hung Lo⁴, Stephen Xu⁴, Elizabeth C Hsia⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM), an anti-tumor necrosis factor alpha (TNFα) monoclonal antibody, in adult patients (pts) w/…
Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 536 • 2018 ACR/ARHP Annual Meeting
Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Masahiro Tada¹, Yutaro Yamada², Koji Mandai³ and Noriaki Hidaka⁴, ¹Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, ²Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopaedic surgery, Osaka City General Hospital, Osaka, Japan
Prevalence and relative factors for frailty in patients with RA from a prospective observational study Background/Purpose: Frailty is defined as degradation of physical and cognition…
Abstract Number: 1088 • 2018 ACR/ARHP Annual Meeting
Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women, and is associated with periods of elevated and suppressed clinical symptoms. SLE…
Abstract Number: 1501 • 2018 ACR/ARHP Annual Meeting
Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
Tate Johnson¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Ted R. Mikuls³ and James R. O'Dell⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Multi-Biomarker Disease Activity (MBDA) score was developed to provide an objective measure of rheumatoid arthritis (RA) disease activity. Demonstrating moderate correlations with conventional…
Abstract Number: 1760 • 2018 ACR/ARHP Annual Meeting
Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis
Rennie L. Rhee¹, Antoine G. Sreih¹, Catherine E. Najem², Peter C. Grayson³, Chunyu Zhao⁴, Kyle Bittinger⁴, Ronald Collman⁵ and Peter A. Merkel⁶, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While prior studies have demonstrated that granulomatosis with polyangiitis (GPA; Wegener’s) is associated with an altered composition of nasal bacteria and that use of…
Abstract Number: 2209 • 2018 ACR/ARHP Annual Meeting
Fluorescence Optical Imaging Xiralite® Is Helpful in the Decision for Rituximab Re-Therapy in Patients with Rheumatoid Arthritis
Sarah Ohrndorf¹, Lisa Ridha², Anne-Marie Glimm³, Gerd R. Burmester¹, Gabriela Schmittat³, Marina Backhaus⁴ and Jens Klotsche⁵, ¹Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany, ⁵Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Rituximab (RTX) is an effective and well-tolerated therapeutic option in rheumatoid arthritis (RA) patients with insufficient response to TNFα inhibitors. However, the exact time…
Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu², Meghan Glynn², Kelechi Emeanuru², Leslie R Harrold³, Sven Richter⁴, Benoit Guerette⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celgene Corporation, Summit, NJ, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting
New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Alessandro Consolaro^1,2, Chiara Trincianti¹, Pieter van Dijkhuizen³, Giedre Januskeviciute⁴, Gabriella Giancane⁵, Alessandra Alongi¹, Joost Swart³, Nicola Ruperto^6,7 and Angelo Ravelli^2,8, ¹University of Genova, Genova, Italy, ²Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ³UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ⁶Universita di Genova Pediatria II, Genova, Italy, ⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁸University of Genova, Genoa, Italy
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…
Abstract Number: 214 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Air Pollution and Disease Activity in Patients with Rheumatoid Arthritis
Tommaso Schioppo¹, Valentina Bollati^2,3, Chiara Favero^2,3, Nicola Ughi¹, Isabella Scotti¹, Valeria Merlino¹, Orazio De Lucia¹, Antonella Murgo¹ and Francesca Ingegnoli^1,3, ¹Division of Clinical Rheumatology, G. Pini Hospital, Milan, Italy, ²EPIGET Lab, Milan, Italy, ³Dept. of Clinical Sciences & Community Health, Università degli Studi di Milano, Milan, Italy
Background/Purpose: Disease remission is considered an achievable target in a significant proportion of patients with rheumatoid arthritis (RA). Nevertheless, diseases flares, that significantly contributes to…
Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Ying Shan², Tamara Lesperance³, Sabrina Rebello², Elaine Karis⁴, Greg Kricorian⁴, Winnie Hua⁵, Neil A. Accortt⁴ and Scott Stryker⁴, ¹Corrona LLC, Waltham, MA, ²Corrona, LLC, Southborough, MA, ³DOCS Global, Inc., North Wales, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…
Abstract Number: 1093 • 2018 ACR/ARHP Annual Meeting
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Rebecca Wood¹, Lauren Guthridge¹, Carla J. Guthridge², Rebecka L. Bourn¹, Hua Chen¹, Wade DeJager¹, Susan R. Macwana¹, Stan Kamp¹, Rufei Lu^1,3, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹, Joel M. Guthridge^1,4 and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a clinically heterogeneous disease oftentimes characterized by a waxing and waning course. Mechanisms of SLE flare remain elusive. This study examined relationships…
Abstract Number: 1598 • 2018 ACR/ARHP Annual Meeting
Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis
Antonio Wong Lam¹, Justine Y. Ye², Dafna D Gladman¹ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Depression and/or anxiety are comorbidities associated with psoriatic arthritis (PsA) that may affect treatment response. We aimed to determine whether the presence of depression/anxiety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].